These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 15842656)
21. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
22. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072 [TBL] [Abstract][Full Text] [Related]
24. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Bowen DT; Frew ME; Hills R; Gale RE; Wheatley K; Groves MJ; Langabeer SE; Kottaridis PD; Moorman AV; Burnett AK; Linch DC Blood; 2005 Sep; 106(6):2113-9. PubMed ID: 15951308 [TBL] [Abstract][Full Text] [Related]
25. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Roumier C; Lejeune-Dumoulin S; Renneville A; Goethgeluck AS; Philippe N; Fenaux P; Preudhomme C Leukemia; 2006 Mar; 20(3):433-6. PubMed ID: 16424869 [TBL] [Abstract][Full Text] [Related]
26. RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. Sano H; Shimada A; Taki T; Murata C; Park MJ; Sotomatsu M; Tabuchi K; Tawa A; Kobayashi R; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y Int J Hematol; 2012 May; 95(5):509-15. PubMed ID: 22407852 [TBL] [Abstract][Full Text] [Related]
27. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Stirewalt DL; Meshinchi S; Kussick SJ; Sheets KM; Pogosova-Agadjanyan E; Willman CL; Radich JP Br J Haematol; 2004 Feb; 124(4):481-4. PubMed ID: 14984498 [TBL] [Abstract][Full Text] [Related]
28. Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients. Nomdedéu J; Carricondo MT; Lasa A; Perea G; Aventin A; Sierra J Haematologica; 2005 Mar; 90(3):412-3. PubMed ID: 15749679 [TBL] [Abstract][Full Text] [Related]
29. [Characteristic Analysis of Adult Acute Myeloid Leukemia Patients with Sheng L; Liu YJ; Zhou JF; Chao HY; Hua HY; Zhou X; Zhao XH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1063-1070. PubMed ID: 39192399 [TBL] [Abstract][Full Text] [Related]
30. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Schnittger S; Schoch C; Dugas M; Kern W; Staib P; Wuchter C; Löffler H; Sauerland CM; Serve H; Büchner T; Haferlach T; Hiddemann W Blood; 2002 Jul; 100(1):59-66. PubMed ID: 12070009 [TBL] [Abstract][Full Text] [Related]
31. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436 [TBL] [Abstract][Full Text] [Related]
32. Flt3 mutations and leukaemia. Kottaridis PD; Gale RE; Linch DC Br J Haematol; 2003 Aug; 122(4):523-38. PubMed ID: 12899708 [No Abstract] [Full Text] [Related]
33. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Christiansen DH; Desta F; Andersen MK; Pedersen-Bjergaard J Genes Chromosomes Cancer; 2007 Jun; 46(6):517-21. PubMed ID: 17330262 [TBL] [Abstract][Full Text] [Related]
34. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Metzner A; Horstmann MA; Fehse B; Ortmeyer G; Niemeyer CM; Stocking C; Mayr GW; Jücker M Gene Ther; 2007 Apr; 14(8):699-703. PubMed ID: 17268534 [TBL] [Abstract][Full Text] [Related]
35. SHP-2 and myeloid malignancies. Tartaglia M; Niemeyer CM; Shannon KM; Loh ML Curr Opin Hematol; 2004 Jan; 11(1):44-50. PubMed ID: 14676626 [TBL] [Abstract][Full Text] [Related]
36. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Martinelli S; Carta C; Flex E; Binni F; Cordisco EL; Moretti S; Puxeddu E; Tonacchera M; Pinchera A; McDowell HP; Dominici C; Rosolen A; Di Rocco C; Riccardi R; Celli P; Picardo M; Genuardi M; Grammatico P; Sorcini M; Tartaglia M Cancer Genet Cytogenet; 2006 Apr; 166(2):124-9. PubMed ID: 16631468 [TBL] [Abstract][Full Text] [Related]
37. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Chen CY; Lin LI; Tang JL; Tsay W; Chang HH; Yeh YC; Huang CF; Chiou RJ; Yao M; Ko BS; Chen YC; Lin KH; Lin DT; Tien HF Leukemia; 2006 Jun; 20(6):1155-8. PubMed ID: 16598312 [No Abstract] [Full Text] [Related]
38. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Abu-Duhier FM; Goodeve AC; Wilson GA; Gari MA; Peake IR; Rees DC; Vandenberghe EA; Winship PR; Reilly JT Br J Haematol; 2000 Oct; 111(1):190-5. PubMed ID: 11091200 [TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Chen W; Jones D; Medeiros LJ; Luthra R; Lin P Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128 [TBL] [Abstract][Full Text] [Related]
40. FLT3 mutations in myeloid sarcoma. Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]